Working… Menu

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03057145
Recruitment Status : Recruiting
First Posted : February 17, 2017
Last Update Posted : August 13, 2019
Eli Lilly and Company
Information provided by (Responsible Party):
Khanh Do, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 25, 2020
Estimated Study Completion Date : February 25, 2023